P. Andrew
YOU?
Author Swipe
View article: Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study Open
NIAID.
View article: Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data Open
Introduction Antiretroviral therapy (ART) prevents and treats, but does not eradicate, HIV. Early ART initiation is associated with post‐ART virologic control, particularly among African women, and anti‐HIV‐1 broadly neutralizing antibodie…
View article: The Local Initiative For Emergency Blood (LIFE-Blood) Study: A mixed-methods, single center exploration of civilian walking blood bank need, feasibility, and safety in a low-resource blood desert
The Local Initiative For Emergency Blood (LIFE-Blood) Study: A mixed-methods, single center exploration of civilian walking blood bank need, feasibility, and safety in a low-resource blood desert Open
Background Billions live in blood deserts, regions where there is effectively no access to blood transfusions. Lodwar County Referral Hospital, set in a rural, low-resource area in northwestern Kenya, is one such blood desert. A walking bl…
View article: A new look at an old warning: Transfusing <scp>ABO</scp> group‐specific red blood cells after large‐volume low‐titer group <scp>O</scp> whole blood in trauma resuscitation
A new look at an old warning: Transfusing <span>ABO</span> group‐specific red blood cells after large‐volume low‐titer group <span>O</span> whole blood in trauma resuscitation Open
View article: Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV Open
VRC07-523LS is a safe and well-tolerated monoclonal antibody (mAb) targeting the CD4 binding site on the HIV envelope (Env) trimer. Efficacy of VRC07-523LS, in combination with mAbs targeting other HIV epitopes, will be evaluated in upcomi…
View article: Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study
Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study Open
View article: It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage
It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage Open
View article: Addressing platelet insecurity – A national call to action
Addressing platelet insecurity – A national call to action Open
Eric Gehrie: Honorarium from Cerus Corporation; Consultancies from Grifols Diagnostics and Instrumentation Laboratories. Editorial Board, Transfusion. Pampee P. Young: Consultancy from Fresenius Kabi; Equity ownership in Eluciderm. Sridhar…
View article: Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial Open
Background Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%…
View article: Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
View article: Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
Correction to "High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials"
View article: Prolyl hydroxylase domain inhibitor is an effective pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock
Prolyl hydroxylase domain inhibitor is an effective pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock Open
View article: Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study)
Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study) Open
Background Persons with opioid use disorders who inject drugs (PWID) in the United States (US) face multiple and intertwining health risks. These include interference with consistent access, linkage, and retention to health care including …
View article: Innovative blood transfusion strategies to address global blood deserts: a consensus statement from the Blood Delivery via Emerging Strategies for Emergency Remote Transfusion (Blood DESERT) Coalition
Innovative blood transfusion strategies to address global blood deserts: a consensus statement from the Blood Delivery via Emerging Strategies for Emergency Remote Transfusion (Blood DESERT) Coalition Open
View article: A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087) Open
Background Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the only bnAb HIV prevention efficacy studies to date, the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, V…
View article: Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial Open
Background Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%…
View article: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
View article: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials Open
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematic…
View article: Genetically engineered transfusable platelets using mRNA lipid nanoparticles
Genetically engineered transfusable platelets using mRNA lipid nanoparticles Open
Platelet transfusions are essential for managing bleeding and hemostatic dysfunction and could be expanded as a cell therapy due to the multifunctional role of platelets in various diseases. Creating these cell therapies will require modif…
View article: Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01 Open
Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials.…
View article: Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01 Open
Broadly neutralizing monoclonal antibodies (mAbs) are being developed for HIV-1 prevention. Hence, these mAbs and licensed oral pre-exposure prophylaxis (PrEP) (tenofovir-emtricitabine) can be concomitantly administered in clinical trials.…
View article: 1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085
1558. Associations between gender identity and solicited adverse events after passive infusion of VRC01 or placebo in HVTN 704/HPTN 085 Open
Background Gender minority individuals are understudied in clinical trials. Realizing the potential of HIV prevention options requires understanding product tolerability across diverse groups vulnerable to HIV acquisition. Within HVTN 704/…
View article: Prolyl hydroxylase domain inhibitor: a potential pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock
Prolyl hydroxylase domain inhibitor: a potential pre-hospital pharmaceutical intervention for trauma and hemorrhagic shock Open
Trauma and hemorrhagic shock-associated pre-hospital deaths are mainly due to hypoperfusion-induced tissue hypoxia leading to irreversible organ dysfunction at or near the point of injury or during transportation prior to receiving definit…
View article: Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation
Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation Open
Extracorporeal membrane oxygenation (ECMO) supplies circulatory support and gas exchange to critically ill patients. Despite the use of systemic anticoagulation, blood exposure to ECMO surfaces causes thromboembolism complications. Inhibit…
View article: Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes
Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes Open
Introduction Trauma patients are susceptible to coagulopathy and dysfunctional immune responses. Mesenchymal stromal cells (MSCs) are at the forefront of the cellular therapy revolution with profound immunomodulatory, regenerative, and the…
View article: A novel, quantitative clot retraction assay to evaluate platelet function
A novel, quantitative clot retraction assay to evaluate platelet function Open
Blood platelets are crucial to prevent excessive bleeding following injury to blood vessels. Platelets are crucial for the formation of clots and for clot strength. Platelet activation involves aggregation, attachment to fibrin and clot re…
View article: Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition Open
View article: Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition Open
BACKGROUND: The phase 2b proof-of-concept Antibody Mediated Prevention (AMP) trials showed that VRC01, an anti-HIV-1 broadly neutralising antibody (bnAb), prevented acquisition of HIV-1 sensitive to VRC01. To inform future study design and…
View article: Dried plasma: An urgent priority for trauma readiness
Dried plasma: An urgent priority for trauma readiness Open
As the US military pivots from years of low-intensity counterinsurgency operations to preparation for large-scale combat operations against a near-peer competitor, the realities of providing medical care to thousands of casualties are sobe…
View article: The cost of doing business in the modern world: Our readiness imperative
The cost of doing business in the modern world: Our readiness imperative Open
Cannon, Jeremy W. MD, SM; Cap, Andrew P. MD, PhD; Rizzo, Julie A. MD; Polk, Travis M. MD Author Information